TNF and non-small cell lung carcinoma: In addition, NSCLC patients with increased IFN-γ, TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12 serum levels at diagnosis and at 3 months post initiation of anti-PD-1 treatment exhibited longer OS [242].